An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)

Brief summary

The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation study up to 28 weeks. The treatment decision for RZB must be made independent of this study enrollment.

Observational study

150 patients
Protocol ID:
Observational model:
Time perspective:

Would you like to know more about this trial?

alert image Please note, participation in the clinical trial is open to patients with the disease or condition under investigation.
Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female


18 Years and older.

Inclusion Criteria:

- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a
dermatologist and presence of moderate to severe psoriasis symptoms according to
physician's clinical judgment at the time of recruitment.

- Participants initiating RZB treatment for psoriasis as per local label. Physician's
decision for treatment with risankizumab must have been reached prior to and
independently of recruitment in the study.

- Participants able to understand and communicate with the investigator and comply with
the requirements of the study.

- Willingness and ability to comply with all study requirements.

Exclusion Criteria:

- Current or recent (within the last 30 days) participation in an interventional clinical

All the cities where the clinical studies are located

Hamilton - L8N 1Y2
Markham - L3P 1X3
Ottawa - K1H 7X3
Peterborough - K9J 5K2
Saint-Jerome - J7Z 7E2
Winnipeg - R3M 3Z4